MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone Meeting Abstract


Authors: Korde, N.; Mailankody, S.; Smith, E. L.; Lendvai, N.; Hassoun, H.; Lesokhin, A.; Hultcrantz, M.; Chung, D. J.; Shah, G. L.; Koehne, G.; Landau, H.; Roshal, M.; Dogan, A.; Giralt, S. A.; Mastey, D.; Evancha, N.; Devlin, S. M.; Landgren, O.
Abstract Title: MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
Meeting Title: 59th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 130
Issue: Suppl. 1
Meeting Dates: 2017 Dec 9-12
Meeting Location: Atlanta, GA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2017-12-07
Language: English
ACCESSION: WOS:000432419700333
PROVIDER: wos
Notes: Meeting Abstract: 3133 -- Source: Wos
MSK Authors
  1. Sergio Andres Giralt
    610 Giralt
  2. Hani Hassoun
    168 Hassoun
  3. Guenther Koehne
    180 Koehne
  4. Heather Jolie Landau
    215 Landau
  5. Nikoletta Lendvai
    97 Lendvai
  6. Alexander Meyer Lesokhin
    133 Lesokhin
  7. David Chung
    99 Chung
  8. Sean McCarthy Devlin
    351 Devlin
  9. Eric Smith
    48 Smith
  10. Ahmet Dogan
    225 Dogan
  11. Mikhail Roshal
    92 Roshal
  12. Carl Ola Landgren
    247 Landgren
  13. Neha Sanat Korde
    74 Korde
  14. Gunjan Lalitchandra Shah
    116 Shah
  15. Donna Mastey
    6 Mastey